Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

VOLUNTARY ANNOUNCEMENT
STRATEGIC COOPERATION FRAMEWORK AGREEMENT

This is a voluntary announcement made by Baijin Life Science Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") to keep the shareholders of the Company (the "**Shareholders**") and potential investors informed of the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the Shareholders and potential investors of the Company that, Beijing Baijin Biotechnology Company Limited ("**Beijing Baijin**") (北京佰金生物科技有限公司), an indirect wholly-owned subsidiary of the Company, has entered into a strategic cooperation framework agreement (the "**Cooperation Framework Agreement**") with Shanghai Guhuan Medical Equipment Company Limited (上海谷環醫療器械有限公司) ("**Guhuan Medical**"), pursuant to which Beijing Baijin intends to invest in Guhuan Medical by way of an equity subscription with a view to establishing a sales channel of branded medical products for the Group's self-operated stores. In addition, Mr. Liang Liang (梁亮) will be proposed to be appointed as the head of the Group's medical business division, responsible for the expansion of its medical product business. The Cooperation Framework Agreement shall expire on 31 December 2026. Either party may terminate the Cooperation Framework Agreement early by giving the other party 10 days' prior notice.

Shanghai Guhuan Medical Equipment Company Limited, which has been deeply engaged in the medical product supply chain for more than ten years, maintains cooperation with high-quality upstream and downstream partners and directly or indirectly holds equity interests in over 30 medical cosmetic institutions. Mr. Liang Liang has extensive experience in the medical cosmetic industry with a track record spanning various segments, such as the medical cosmetic supply chain, the operation of medical institutions and investment management.

The Board is of the view that entering into the Cooperation Framework Agreement will support the Group in optimising the market ecosystem for its medical products—from research and development through to the establishment of proprietary sales channels—and will help to stabilise and expand the Group's revenue streams.

The Board wishes to emphasise that the Cooperation Framework Agreement only sets out the preliminary cooperation intentions of Beijing Baijin and Guhuan Medical, which does not constitute any substantive right and obligation of any parties thereto and is subject to further formal agreement(s) and/or arrangement(s) to be entered into by the parties, which may or may not materialise. Where necessary, further announcement(s) will be made by the Company as and when appropriate in compliance with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 1 December 2025

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Mr. Lee Ka Leung Daniel as independent non-executive Directors.